CASP4 and COVID-19: BCL2L1 is known to be highly upregulated in inflamed tissue [55], and it was found to be upregulated in COVID-19 and both single and recurrent VTE (Figure 2C), while CASP4 directs the noncanonical upregulation of inflammasomes [56].